In recent years, due to its clinical treatment for certain tumors and obvious therapeutic effect, thalidomide has gained support, but the mechanism of tumor inhibition is unclear and widespread clinical application is restricted.This study selected OPN as a main target and showed that thalidomide is able to damage human hepatocellular carcinoma cells and downregulate the expression of osteopontin. Here, SPP1 is linked to neoplasm.